Abstract: The invention relates, in part, to compounds, compositions, and methods to assess characteristics of mitochondrial antiviral-signaling (MAVS) polypeptides and also to methods of modulating MAVS polypeptide characteristics. In addition, the invention relates, in part, to assays to assess characteristics of polypeptides.

Abstract: Organometallic compounds comprising a chloroquinoline moiety and uses of the compounds. The compounds are, for example, manganese or rhenium complexes of a ligand comprising a chloroquinoline moiety. The compounds can be used in, for example, methods of inhibiting cell growth.

Abstract: Provided herein, in some embodiments, are compositions of Zika-specific antibodies and antigen-binding fragments thereof and methods of using said antibodies and antigen-binding fragments.

Abstract: The present invention provides systems and methods for the decellularization and recellularization of tissue segments. In certain instances the invention comprises coating or sealing decellularized tissue segments with a cross-linked alginate hydrogel. The present invention also provides a decellularization kit, which may be used to generate decellularized tissue segments for high throughput studies. Also included are compositions and methods of tissue sealants comprising methacrylated alginate.

Abstract: Catheters, systems, and related methods for optimized for mapping, minimizing, and treating cardiac fibrillation in a patient, including an array of at least one stacked electrode pair, each electrode pair including a first electrode and a second electrode, wherein each electrode pair is configured to be orthogonal to a surface of a cardiac tissue substrate, wherein each first electrode is in contact with the surface to record a first signal, and wherein each second electrode is separated from the first electrode by a distance which enables the second electrode to record a second signal, wherein the catheter is configured to obtain one or more measurements from at least a first signal and a second signal in response to electrical activity in the cardiac tissue substrate indicative of a number of electrical circuit cores and distribution of the electrical circuit cores for a duration across the cardiac tissue substrate.

Abstract: The invention includes, in part, methods and compounds for diagnosing diseases and conditions characterized by altered threonyl-tRNA synthetase (TARS) activity, which include, but are not limited to diseases and conditions in which angiogenesis is altered. In some embodiments of the invention, a level of a TARS molecule is determined and compared to a control level of TARS to assess onset, progression, and/or regression of a disease or condition associated with altered TARS activity.

Abstract: The invention relates, in part, to methods and compositions that are useful to modulate metabolic function of cells in vivo or in vitro. In some aspects the invention includes methods and/or compositions that increase metabolism in cells, tissues, organs, and/or subjects. In certain aspects the invention includes methods and/or compositions useful to decrease metabolism in cells, tissues, organs, and/or in subjects.

Abstract: In various embodiments, a three-dimensional (3D) printed tripolar antenna fabricated through additive manufacturing techniques to match the geometries of various commercial wireless node packages is provided. The antenna systems are designed to mitigate harsh channel conditions by implementing polarization diversity between three mutually orthogonal monopoles.

Abstract: Methods and products for producing an antigen specific immune response are provided. The methods involve administration of a caspase inhibitor to a subject.

Abstract: The invention features compositions featuring (a) one or more of connective tissue growth factor (CTGF) and human C-terminal CTGF peptide; and (b) one or more of insulin and IGF-1; and methods of using such compositions to reduce cardiac tissue damage associated with an ischemic event or to enhance engraftment of a cell in a cardiac tissue.

Abstract: Systems, apparatuses, and methods for generating hot gases based on catalyzation involving flowing catalyst. Catalysis occurs in a flow-type mixing catalyzation channel in which a liquid catalyst mixes with a liquid reactant flowing in a desired flow regime, such as a striated (laminar) flow regime or a slug flow regime. Devices such as micro-thrusters for satellite and other applications and hot gas generators for powering another device, such as an electrical generator, can be made using one or more flow-type mixing catalyzation channels.

Abstract: The invention relates, in part, to methods and compositions that are useful to modulate metabolic function of cells in vivo or in vitro. In some aspects the invention includes methods and/or compositions that increase metabolism in cells, tissues, organs, and/or subjects. In certain aspects the invention includes methods and/or compositions useful to decrease metabolism in cells, tissues, organs, and/or in subjects.

Abstract: Methods and compounds useful to treat drug-induced diseases and conditions are provided. Methods of administering one or more MCJ-inhibiting compounds to decrease MCJ polypeptide activity in cells, tissues, and/or subjects as a treatment for a drug-induced disease or condition are provided.

Abstract: A vibrating magnetic antenna for generating reversable magnetic dipoles is provided. Soft magnetic materials are used to project the magnetic field as the magnet moves linearly between soft magnetic stators arranged in a “Y” configuration. The soft magnetic stators include a nickel-iron alloy, having high magnetic permeability. Also provided is a magnetic coupling circuit for upshifting the frequency of the magnetic field.

Abstract: The invention includes, in part, methods and compounds for treating cancer including, but not limited to gliomas, melanomas, and neuroblastomas. In some embodiments of the invention, a glyceryltriacetate compound is administered to a subject in an amount effective to treat or prevent a cancer in the subject.

Abstract: The present invention generally relates to systems and methods for treating certain oxidative stress conditions. In one aspect, compositions and methods of the invention can be used to treat a subject having an oxidative stress condition, for example, a subject having pulmonary fibrosis. In some embodiments, an inhibitor of ERp57 (for example, thiomuscimol) and/or an inhibitor of GSTP (for example, TLK-199) may be used to treat the subject. Also provided in certain aspects of the present invention are kits for such therapies, methods for promoting such therapies, and the like.

Abstract: The invention features compositions featuring (a) one or more of connective tissue growth factor (CTGF) and human C-terminal CTGF peptide; and (b) one or more of insulin and IGF-1; and methods of using such compositions to reduce cardiac tissue damage associated with an ischemic event or to enhance engraftment of a cell in a cardiac tissue.

Abstract: Compositions and methods are provided for determining platelet reactivity where the levels of Fc?RIIa on the surface of platelets is measured and if the levels of Fc?RIIa are greater than a reference value, the platelets have enhanced reactivity.

Abstract: Methods and compounds useful to treat drug-induced diseases and conditions are provided. Methods of administering one or more MCJ-inhibiting compounds to decrease MCJ polypeptide activity in cells, tissues, and/or subjects as a treatment for a drug-induced disease or condition are provided.

Abstract: The invention features compositions comprising agents having cardiac protective activity isolated from epicardial progenitor cells and derivatives thereof, and methods for the use of such compositions.